"Antigens, CD34" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Glycoproteins found on immature hematopoietic cells and endothelial cells. They are the only molecules to date whose expression within the blood system is restricted to a small number of progenitor cells in the bone marrow.
| Descriptor ID |
D018952
|
| MeSH Number(s) |
D23.050.301.264.035.134 D23.101.100.110.134
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antigens, CD34".
Below are MeSH descriptors whose meaning is more specific than "Antigens, CD34".
This graph shows the total number of publications written about "Antigens, CD34" by people in this website by year, and whether "Antigens, CD34" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 1995 | 0 | 4 | 4 |
| 1996 | 1 | 1 | 2 |
| 1997 | 1 | 1 | 2 |
| 1998 | 0 | 2 | 2 |
| 1999 | 2 | 2 | 4 |
| 2000 | 1 | 3 | 4 |
| 2001 | 4 | 5 | 9 |
| 2002 | 0 | 2 | 2 |
| 2003 | 0 | 2 | 2 |
| 2004 | 0 | 5 | 5 |
| 2005 | 0 | 2 | 2 |
| 2006 | 0 | 4 | 4 |
| 2007 | 1 | 1 | 2 |
| 2008 | 1 | 4 | 5 |
| 2009 | 1 | 5 | 6 |
| 2010 | 1 | 2 | 3 |
| 2011 | 0 | 4 | 4 |
| 2012 | 1 | 1 | 2 |
| 2013 | 1 | 4 | 5 |
| 2014 | 1 | 3 | 4 |
| 2015 | 4 | 3 | 7 |
| 2016 | 1 | 3 | 4 |
| 2017 | 1 | 3 | 4 |
| 2018 | 0 | 2 | 2 |
| 2022 | 0 | 3 | 3 |
| 2023 | 0 | 1 | 1 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antigens, CD34" by people in Profiles.
-
Transplant Outcomes in Myelofibrosis: Impact of Donor Type (Cord Blood Grafts Supported by CD34+ selected Cells [Haplo-Cord] Versus Matched Donors). Transplant Cell Ther. 2024 Nov; 30(11):1100.e1-1100.e11.
-
CRISPR-Cas9 Editing of the HBG1 and HBG2 Promoters to Treat Sickle Cell Disease. N Engl J Med. 2023 Aug 31; 389(9):820-832.
-
Dynamic EASIX scores closely predict nonrelapse mortality after allogeneic hematopoietic cell transplantation. Blood Adv. 2022 11 22; 6(22):5898-5907.
-
EGR1 Haploinsufficiency Confers a Fitness Advantage to Hematopoietic Stem Cells Following Chemotherapy. Exp Hematol. 2022 11; 115:54-67.
-
CD34+ -selected hematopoietic stem cell transplant conditioned with a myeloablative regimen in patients with advanced myelofibrosis. Bone Marrow Transplant. 2022 07; 57(7):1101-1107.
-
Plerixafor alone for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells. Blood Adv. 2019 03 26; 3(6):875-883.
-
Bone marrow hematopoietic dysfunction in untreated chronic lymphocytic leukemia patients. Leukemia. 2019 03; 33(3):638-652.
-
Safety and efficacy of plerixafor dose escalation for the mobilization of CD34+ hematopoietic progenitor cells in patients with sickle cell disease: interim results. Haematologica. 2018 05; 103(5):770-777.
-
Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared with Matched Unrelated Donor Stem Cells in Older Adults. Biol Blood Marrow Transplant. 2018 05; 24(5):997-1004.
-
Impact of Toxicity on Survival for Older Adult Patients after CD34+ Selected Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2018 01; 24(1):142-149.